Skip Navigation

European Heart Journal 1999 20(4):263-268; doi:10.1053/euhj.1999.1193
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Caro, J.
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caro, J.
Right arrow Articles by Shepherd, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS

J. Carof2, W. Klittich, A. McGuire, I. Ford, D. Pettitt, J. Norrie and J. Shepherd

WOSCOPS Economic Analysis Committee, f1

revised June 9, 1998; accepted June 10, 1998

Abstract

Aims The results of the West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated the clinical benefit of using pravastatin for the primary prevention of cardiovascular disease in hypercholesterolaemic men. To inform decision makers, who must also consider costs, this study assesses the economic efficiency of such an intervention in a broad range of countries.

Methods and Results A generalized model of cardiovascular disease prevention was used to estimate the cost-effectiveness of primary prevention with pravastatin compared to diet alone. This model follows a cohort of hypercholesterolaemic men over a given period quantifying the effect in terms of the avoidance of cardiovascular disease based on treatment-specific risks derived from WOSCOPS data and extensive record-linkage data on disease-specific survival. Country-specific costs are accounted for by expressing all such parameters in terms of the ratio of monthly treatment to that of managing a myocardial infarction. Over a broad range of inputs the cost-effectiveness ratios remain below $25000 per life years gained, regardless of country. Subgroups with even better economic efficacy can be defined on the basis of higher baseline risk.

Conclusions In contrast to some previous reports, this analysis based on trial data demonstrates that pravastatin provides not only an effective means of primary cardio-vascular disease prevention, but also an efficient one.

Key Words: Lipids • cost-effectiveness • cholesterol-lowering • coronary heart disease • prevention • general economic model

f2 Correspondence: Dr J. Caro, 336 Baker Avenue, Concord, MA 01742, U.S.A.

f1 See Appendix for Committee members.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 QJMHome page
Z. Kabir, K. Bennett, E. Shelley, B. Unal, J. Critchley, J. Feely, and S. Capewell
The population mortality benefits of maximizing the number of eligible patients receiving appropriate cardiology treatments in Ireland
QJM, August 1, 2006; 99(8): 523 - 530.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. J. Budoff, S. Achenbach, and A. Duerinckx
Clinical utility of computed tomography and magnetic resonance techniques for noninvasive coronary angiography
J. Am. Coll. Cardiol., December 3, 2003; 42(11): 1867 - 1878.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
J. J. Caro, K. F. Huybrechts, and I. Duchesne
Management Patterns and Costs of Acute Ischemic Stroke : An International Study
Stroke, March 1, 2000; 31(3): 582 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. M. Grundy, J. I. Cleeman, B. M. Rifkind, L. H. Kuller, and for the Coordinating Committee of the National Cho
Cholesterol Lowering in the Elderly Population
Arch Intern Med, August 9, 1999; 159(15): 1670 - 1678.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.